This three-part webcast series is targeted to medical oncologists, molecular pathologists, and other clinicians who are involved in diagnosis and treatment of HER2+ gastric cancer. Moderated expertly by the series Chair, Dr. David Ilson from Memorial Sloan Kettering, our knowledgeable faculty will examine the latest testing guidelines and clinical trial data, exploring the burgeoning evidentiary base in support of an expanded role for antibody-drug conjugates in oncology, and specifically in HER2+ gastric cancer.
Click on a Thumbnail Below to Complete Each Webcast in the Series.
Earn ACCME Credit for each Webcast.
